Lisa M Hess1, Helen Q Huang2, Alexandra L Hanlon3, William R Robinson4, Rhonda Johnson5, Setsuko K Chambers6, Robert S Mannel7, Larry Puls8, Susan A Davidson9, Michael Method10, Shashikant Lele11, Laura Havrilesky12, Tina Nelson13, David S Alberts14. 1. Indiana University School of Medicine, Indianapolis, IN 46202, United States. Electronic address: lmhess@iupui.edu. 2. NRG Oncology/Gynecologic Oncology Group Statistics and Data Center, Buffalo, NY, United States. Electronic address: hhuang@gogstats.org. 3. University of Pennsylvania, Philadelphia, PA, United States. Electronic address: al_hanlon@comcast.net. 4. Tulane University, New Orleans, LA, United States. Electronic address: wrobinso@tulane.edu. 5. Kansas University Medical Center, Kansas City, KS, United States. Electronic address: rjohnson7@kumc.edu. 6. University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: schambers@uacc.arizona.edu. 7. The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: Robert-mannel@ouhsc.edu. 8. Greenville CCOP, Greenville, NC, United States. Electronic address: lpuls@ghs.org. 9. University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, CO, United States. Electronic address: susan.davidson@ucdenver.edu. 10. Northern Indiana CCOP, Mishawaka, IN, United States. Electronic address: mmethod@mhopc.com. 11. Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: Shashi.lele@roswellpark.org. 12. Duke University Medical Center, Durham, NC, United States. Electronic address: havri001@mc.duke.edu. 13. The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: tina-nelson@ouhsc.edu. 14. University of Arizona Cancer Center, Tucson, AZ, United States. Electronic address: dalberts@uacc.arizona.edu.
Abstract
OBJECTIVES: Changes in cognitive function have been identified in and reported by many cancer survivors. These changes have the potential to impact patient quality of life and functional ability. This prospective longitudinal study was designed to quantify the incidence of change in cognitive function in newly diagnosed ovarian cancer patients throughout and following primary chemotherapy. METHODS: Eligible patients had newly diagnosed, untreated ovarian cancer and had planned to receive chemotherapy. Web-based and patient reported cognitive assessments and quality of life questionnaires were conducted prior to chemotherapy, prior to cycle four, after cycle six, and six months after completion of primary therapy. RESULTS: Two-hundred-thirty-one evaluable patients entered this study between May 2010 and October 2011. At the cycle 4 time point, 25.2% (55/218) of patients exhibited cognitive impairment in at least one domain. At the post-cycle 6 and 6-month follow up time points, 21.1% (44/208) and 17.8% (30/169) of patients, respectively, demonstrated impairment in at least one domain of cognitive function. There were statistically significant, but clinically small, improvements in processing speed (p<0.001) and attention (p<0.001) but not in motor response time (p=0.066), from baseline through the six-month follow up time period. CONCLUSIONS: This was a large, prospective study designed to measure cognitive function in ovarian cancer. A subset of patients had evidence of cognitive decline from baseline during chemotherapy treatment in this study as measured by the web-based assessment; however, changes were generally limited to no more than one domain.
OBJECTIVES: Changes in cognitive function have been identified in and reported by many cancer survivors. These changes have the potential to impact patient quality of life and functional ability. This prospective longitudinal study was designed to quantify the incidence of change in cognitive function in newly diagnosed ovarian cancerpatients throughout and following primary chemotherapy. METHODS: Eligible patients had newly diagnosed, untreated ovarian cancer and had planned to receive chemotherapy. Web-based and patient reported cognitive assessments and quality of life questionnaires were conducted prior to chemotherapy, prior to cycle four, after cycle six, and six months after completion of primary therapy. RESULTS: Two-hundred-thirty-one evaluable patients entered this study between May 2010 and October 2011. At the cycle 4 time point, 25.2% (55/218) of patients exhibited cognitive impairment in at least one domain. At the post-cycle 6 and 6-month follow up time points, 21.1% (44/208) and 17.8% (30/169) of patients, respectively, demonstrated impairment in at least one domain of cognitive function. There were statistically significant, but clinically small, improvements in processing speed (p<0.001) and attention (p<0.001) but not in motor response time (p=0.066), from baseline through the six-month follow up time period. CONCLUSIONS: This was a large, prospective study designed to measure cognitive function in ovarian cancer. A subset of patients had evidence of cognitive decline from baseline during chemotherapy treatment in this study as measured by the web-based assessment; however, changes were generally limited to no more than one domain.
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Lisa M Hess; Setsuko K Chambers; Kenneth Hatch; Alton Hallum; Mike F Janicek; Joseph Buscema; Matthew Borst; Cynthia Johnson; Lisa Slayton; Yuda Chongpison; David S Alberts Journal: J Support Oncol Date: 2010 Nov-Dec
Authors: Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437
Authors: David M Erlanger; Tanya Kaushik; Donna Broshek; Jason Freeman; Daniel Feldman; Joanne Festa Journal: J Head Trauma Rehabil Date: 2002-10 Impact factor: 2.710
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Camille C Gunderson; Adam C Walter; Rachel Ruskin; Kai Ding; Kathleen N Moore Journal: Support Care Cancer Date: 2016-06-15 Impact factor: 3.603
Authors: D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin Journal: Brain Imaging Behav Date: 2017-12 Impact factor: 3.978
Authors: Sabine Deprez; Shelli R Kesler; Andrew J Saykin; Daniel H S Silverman; Michiel B de Ruiter; Brenna C McDonald Journal: J Natl Cancer Inst Date: 2018-03-01 Impact factor: 13.506